New hope for stomach cancer: targeted drug HS-20093 enters human trials

NCT ID NCT07462923

Recruiting now Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests HS-20093, a drug designed to seek out and attack cancer cells by targeting a protein called B7-H3. It is for people with advanced stomach or gastroesophageal junction cancer that has not responded to or stopped responding to standard treatments. The study will enroll about 40 participants to check safety, tolerability, and whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20093 (an antibody-drug conjugate that targets B7-H3 on tumor cells)
What this could lead to: If successful, this could point toward a new treatment option for advanced gastric cancer that has stopped responding to standard therapies.
What could go wrong: This is an early Phase 1b trial with only 40 participants, so it is too small to prove effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.